CGON

Business Context and Reporting Period

Company: CG Oncology, Inc. (CGON)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: CG Oncology is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec for bladder cancer. The company has no approved products and generates revenue solely from research and collaboration agreements. In January 2024, the company completed its Initial Public Offering (IPO) and converted all redeemable convertible preferred stock to common stock.

Key Financial Metrics

Note: Revenue consists entirely of research and collaboration income. The company reported significant interest income ($6.9M for Q2; $12.5M for YTD) due to high cash balances from the IPO.

Material Changes vs. Prior Period

• Capital Structure: The company completed its IPO in January 2024, raising net proceeds of approximately $399.6 million. Consequently, all Series A-1 through F redeemable convertible preferred stock converted to common stock, eliminating the mezzanine equity section present in the prior year.
• Liquidity: Total cash, cash equivalents, and marketable securities increased from $187.7 million (Dec 31, 2023) to $552.9 million (June 30, 2024).
• Operating Expenses:
  • R&D Expenses: Increased to $18.5 million (Q2 2024) from $9.8 million (Q2 2023), driven by higher external clinical trial costs and increased headcount.
  • G&A Expenses: Increased to $7.5 million (Q2 2024) from $2.5 million (Q2 2023), primarily due to personnel costs and professional fees associated with public company operations.
• Net Loss: Net loss for the six months ended June 30, 2024, was $35.8 million compared to $20.3 million in the prior year period. The increase is attributed to higher operating expenses, partially offset by increased interest income.

Outlook, Risks, and Management Commentary

• Clinical Progress: The company has completed enrollment for the BOND-003 Phase 3 trial in high-risk BCG-unresponsive NMIBC and expects to report primary data by the end of 2024. Positive final results were reported in May 2024 for the CORE-001 Phase 2 trial (combination with pembrolizumab). An expanded access program was initiated in June 2024.
• Liquidity Outlook: Management estimates that existing cash and marketable securities ($552.9 million) are sufficient to fund operations through 2027.
• Risks:
  • Legal Proceedings: ANI Pharmaceuticals, Inc. filed a complaint in March 2024 seeking a declaratory judgment regarding royalty obligations on cretostimogene. The company disputes the allegations and is defending the matter.
  • Profitability: The company has incurred losses since inception and expects to continue incurring significant losses as it advances clinical trials and prepares for potential commercialization.
  • Regulatory Approval: Future revenue is contingent upon FDA approval of cretostimogene, which is not guaranteed.

Key Facts for Investor Verification

• Runway: Verify the sustainability of the $552.9 million cash position against the projected burn rate through 2027.
• Clinical Data: Monitor the timing and results of the primary data readout for the BOND-003 Phase 3 trial expected by end of 2024.
• Legal Contingency: Track the status of the litigation with ANI Pharmaceuticals regarding potential royalty liabilities.
• Expense Growth: Assess the trajectory of R&D and G&A expenses as the company scales operations post-IPO.
• Revenue Recognition: Confirm that revenue remains limited to collaboration milestones and does not include product sales.